NK-104-CR

DRUG2 trials

Sponsors

Kowa Research Institute, Inc.

Conditions

DyslipidemiaHyperlipidemia

Phase 3

Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia

WithdrawnNCT02670434

Kowa Research Institute, Inc.Dyslipidemia, Hyperlipidemia

Start: 2016-01-31End: 2017-10-31Updated: 2021-05-10

Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia

WithdrawnNCT02799758

Kowa Research Institute, Inc.Dyslipidemia, Hyperlipidemia

Start: 2016-02-29End: 2017-11-30Updated: 2021-05-10